Marie-Cécile Le Deley1, Michael Paulussen2, Ian Lewis2, Bernadette Brennan2, Andreas Ranft2, Jeremy Whelan2, Gwénaël Le Teuff2, Jean Michon2, Ruth Ladenstein2, Perrine Marec-Bérard2, Henk van den Berg2, Lars Hjorth2, Keith Wheatley2, Ian Judson2, Heribert Juergens2, Alan Craft2, Odile Oberlin2, Uta Dirksen2. 1. Odile Oberlin, Gustave Roussy Institute, Villejuif; Marie-Cécile Le Deley, Université Paris-Sud, Le Kremlin-Bicêtre; Jean Michon, Institut Curie, Paris; Perrine Marec-Bérard, Centre Léon-Bérard, Lyon, France; Michael Paulussen, Vestische Kinder-und Jugendklinik Datteln, Witten/Herdecke University, Datteln; Andreas Ranft, Heribert Juergens, and Uta Dirksen, University Hospital Münster, Münster, Germany; Ian Lewis, Alder Hey Children's National Health Service Foundation Trust, Liverpool; Bernadette Brennan, Royal Manchester Children's Hospital, Manchester; Jeremy Whelan, University College London Hospital National Health Service Foundation Trust; Ian Judson, The Royal Marsden Hospital, London; Keith Wheatley, University of Birmingham, Birmingham; Alan Craft, Royal Victoria Infirmary, Newcastle, United Kingdom; Ruth Ladenstein, St Anna Children's Cancer Research Institute, Vienna, Austria; Henk van den Berg, Emma Children Hospital AMC, Amsterdam, the Netherlands; and Lars Hjorth, Skåne University Hospital, Lund University, Lund, Sweden. marie-cecile.ledeley@igr.fr. 2. Odile Oberlin, Gustave Roussy Institute, Villejuif; Marie-Cécile Le Deley, Université Paris-Sud, Le Kremlin-Bicêtre; Jean Michon, Institut Curie, Paris; Perrine Marec-Bérard, Centre Léon-Bérard, Lyon, France; Michael Paulussen, Vestische Kinder-und Jugendklinik Datteln, Witten/Herdecke University, Datteln; Andreas Ranft, Heribert Juergens, and Uta Dirksen, University Hospital Münster, Münster, Germany; Ian Lewis, Alder Hey Children's National Health Service Foundation Trust, Liverpool; Bernadette Brennan, Royal Manchester Children's Hospital, Manchester; Jeremy Whelan, University College London Hospital National Health Service Foundation Trust; Ian Judson, The Royal Marsden Hospital, London; Keith Wheatley, University of Birmingham, Birmingham; Alan Craft, Royal Victoria Infirmary, Newcastle, United Kingdom; Ruth Ladenstein, St Anna Children's Cancer Research Institute, Vienna, Austria; Henk van den Berg, Emma Children Hospital AMC, Amsterdam, the Netherlands; and Lars Hjorth, Skåne University Hospital, Lund University, Lund, Sweden.
Abstract
PURPOSE:Relative efficacy and toxicity of cyclophosphamide compared with ifosfamide are debatable. The Euro-EWING99-R1 trial asked whether cyclophosphamide may replace ifosfamide in combination with vincristine and dactinomycin (vincristine, dactinomycin, and cyclophosphamide [VAC] v vincristine, dactinomycin, and ifosfamide [VAI]) after an intensive induction chemotherapy containing vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in standard-risk localized disease (NCT00020566). METHODS: Standard-risk Ewing sarcomas were localized tumors with either a good histologic response to chemotherapy (< 10% cells) or small tumors (< 200 mL) resected at diagnosis or receiving radiotherapy alone as local treatment. Patients entered the trial after six VIDE+1 VAI courses. Allocated treatment was either 7 VAC courses with 1.5 g/m(2) of cyclophosphamide or seven VAI-courses with 6 g/m(2) ifosfamide. The limit of noninferiority was set at -8.5% for the 3-year event-free survival rate (EFS), equivalent to 1.43 in terms of the hazard ratio of event (HR(event)). RESULTS: This large international trial recruited 856 patients between February 2000 and March 2010 (n = 431 receiving VAC and n = 425 receiving VAI). With a median follow-up of 5.9 years, the 3-year EFSs were 75.4% and 78.2%, respectively, the 3-year EFS difference was -2.8% (91.4% CI, -7.8 to 2.2%), the HR(event) was 1.12 (91.4% CI, 0.89 to 1.41), and the HR(death) was 1.09 (91.4% CI, 0.84 to 1.42; intention-to-treat). The HR(event) was 1.22 (91.4% CI, 0.96 to 1.54) on the per-protocol population. Major treatment modifications were significantly less frequent in the VAC arm (< 1%) than in the VAI arm (7%), mainly resulting from toxicity. Patients experienced more frequent thrombocytopenia in the VAC arm (45% v 35%) but fewer grade 2 to 4 acute tubular toxicities (16% v 31%). CONCLUSION:Cyclophosphamide may be able to replace ifosfamide in consolidation treatment of standard-risk Ewing sarcoma. However, some uncertainty surrounding the noninferiority of VAC compared with VAI remains at this stage. The ongoing comparative evaluation of long-term renal and gonadal toxicity is crucial to decisions regarding future patients.
RCT Entities:
PURPOSE: Relative efficacy and toxicity of cyclophosphamide compared with ifosfamide are debatable. The Euro-EWING99-R1 trial asked whether cyclophosphamide may replace ifosfamide in combination with vincristine and dactinomycin (vincristine, dactinomycin, and cyclophosphamide [VAC] v vincristine, dactinomycin, and ifosfamide [VAI]) after an intensive induction chemotherapy containing vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in standard-risk localized disease (NCT00020566). METHODS: Standard-risk Ewing sarcomas were localized tumors with either a good histologic response to chemotherapy (< 10% cells) or small tumors (< 200 mL) resected at diagnosis or receiving radiotherapy alone as local treatment. Patients entered the trial after six VIDE+1 VAI courses. Allocated treatment was either 7 VAC courses with 1.5 g/m(2) of cyclophosphamide or seven VAI-courses with 6 g/m(2) ifosfamide. The limit of noninferiority was set at -8.5% for the 3-year event-free survival rate (EFS), equivalent to 1.43 in terms of the hazard ratio of event (HR(event)). RESULTS: This large international trial recruited 856 patients between February 2000 and March 2010 (n = 431 receiving VAC and n = 425 receiving VAI). With a median follow-up of 5.9 years, the 3-year EFSs were 75.4% and 78.2%, respectively, the 3-year EFS difference was -2.8% (91.4% CI, -7.8 to 2.2%), the HR(event) was 1.12 (91.4% CI, 0.89 to 1.41), and the HR(death) was 1.09 (91.4% CI, 0.84 to 1.42; intention-to-treat). The HR(event) was 1.22 (91.4% CI, 0.96 to 1.54) on the per-protocol population. Major treatment modifications were significantly less frequent in the VAC arm (< 1%) than in the VAI arm (7%), mainly resulting from toxicity. Patients experienced more frequent thrombocytopenia in the VAC arm (45% v 35%) but fewer grade 2 to 4 acute tubular toxicities (16% v 31%). CONCLUSION:Cyclophosphamide may be able to replace ifosfamide in consolidation treatment of standard-risk Ewing sarcoma. However, some uncertainty surrounding the noninferiority of VAC compared with VAI remains at this stage. The ongoing comparative evaluation of long-term renal and gonadal toxicity is crucial to decisions regarding future patients.
Authors: A Raciborska; K Bilska; K Drabko; E Michalak; R Chaber; M Pogorzała; K Połczyńska; G Sobol; M Wieczorek; K Muszyńska-Rosłan; M Rychlowska-Pruszyńska; C Rodriguez-Galindo; M Dziuk Journal: Clin Transl Oncol Date: 2015-08-07 Impact factor: 3.405
Authors: Christoph Minichsdorfer; Oskar Steinbrecher; Marita KÖlz; Maximilian Schmid; Markus Raderer; Thomas Brodowicz; Wolfgang Lamm Journal: In Vivo Date: 2021 Jan-Feb Impact factor: 2.155
Authors: Leo Mascarenhas; Judy L Felgenhauer; Mason C Bond; Doojduen Villaluna; Joseph Dominic Femino; Nadia N Laack; Sarangarajan Ranganathan; James Meyer; Richard B Womer; Richard Gorlick; Mark D Krailo; Neyssa Marina Journal: Pediatr Blood Cancer Date: 2015-11-18 Impact factor: 3.167
Authors: Cecilia G Ethun; Alexandra G Lopez-Aguiar; Jeffery M Switchenko; Theresa W Gillespie; Keith A Delman; Charles A Staley; Shishir K Maithel; Kenneth Cardona Journal: Ann Surg Oncol Date: 2019-09-09 Impact factor: 5.344
Authors: Jeremy Whelan; Marie-Cecile Le Deley; Uta Dirksen; Gwénaël Le Teuff; Bernadette Brennan; Nathalie Gaspar; Douglas S Hawkins; Susanne Amler; Sebastian Bauer; Stefan Bielack; Jean-Yves Blay; Stefan Burdach; Marie-Pierre Castex; Dagmar Dilloo; Angelika Eggert; Hans Gelderblom; Jean-Claude Gentet; Wolfgang Hartmann; Wolf-Achim Hassenpflug; Lars Hjorth; Marta Jimenez; Thomas Klingebiel; Udo Kontny; Jarmila Kruseova; Ruth Ladenstein; Valerie Laurence; Cyril Lervat; Perrine Marec-Berard; Sandrine Marreaud; Jean Michon; Bruce Morland; Michael Paulussen; Andreas Ranft; Peter Reichardt; Hendrik van den Berg; Keith Wheatley; Ian Judson; Ian Lewis; Alan Craft; Heribert Juergens; Odile Oberlin Journal: J Clin Oncol Date: 2018-09-06 Impact factor: 44.544